SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IVAX Insider Trading -- Ignore unavailable to you. Want to Upgrade?

To: flickerful who wrote (464)1/22/1998 9:34:00 AM
From: Roader  Respond to of 756
 
Do you have an opening price?



To: flickerful who wrote (464)1/22/1998 1:06:00 PM
From: 5,17,37,5,101,...  Respond to of 756
 
Your are right. It is stronger than I thought it would be, not sloppy at all. Yikes! On a little weakness (7 1/2?) I may repurchase what I sold yesterday afternoon.
Jackson



To: flickerful who wrote (464)1/23/1998 5:23:00 PM
From: Ronald Allen  Read Replies (1) | Respond to of 756
 
After the close, IVAX announced that they received approval from the FDA for its application for prochlorperazine, the generic equivalent of Compazine which is produced by SmithKline Beecham. They have begun shipping the product.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News